143 related articles for article (PubMed ID: 35848529)
1. [18F]FDG PET/CT and CA-125 in the evaluation of ovarian cancer relapse or persistence: is there any correlation?
Dondi F; Albano D; Bertagna F; Giubbini R
Nucl Med Rev Cent East Eur; 2022; 25(2):78-84. PubMed ID: 35848529
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers and
Dondi F; Albano D; Bertagna F; Giubbini R
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):287-292. PubMed ID: 34425969
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
[TBL] [Abstract][Full Text] [Related]
4. 2-[
Albano D; Calabrò A; Dondi F; Bertagna F
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399491
[No Abstract] [Full Text] [Related]
5. 2-[
Albano D; Camoni L; Rodella C; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e277-e283. PubMed ID: 33386279
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.
Albano D; Bosio G; Treglia G; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):77-84. PubMed ID: 28822997
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
[TBL] [Abstract][Full Text] [Related]
8. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
10. The value of [18F]FDG PET/CT examination in the detection and differentiation of recurrent ovarian cancer.
Kosinska M; Misiewicz P; Kalita K; Fijuth J; Foks M; Kuncman L; Gottwald L
Nucl Med Rev Cent East Eur; 2023; 26(0):98-105. PubMed ID: 37525539
[TBL] [Abstract][Full Text] [Related]
11. Metabolic behavior and prognostic role of pretreatment 18F-FDG PET/CT in gist.
Albano D; Bosio G; Tomasini D; Bonù M; Giubbini R; Bertagna F
Asia Pac J Clin Oncol; 2020 Oct; 16(5):e207-e215. PubMed ID: 32762133
[TBL] [Abstract][Full Text] [Related]
12. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma.
Ye S; Liu S; Zhou S; Xiang L; Wu X; Yang H
Cancer Biomark; 2020; 27(2):189-194. PubMed ID: 31796665
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
Antunovic L; Cimitan M; Borsatti E; Baresic T; Sorio R; Giorda G; Steffan A; Balestreri L; Tatta R; Pepe G; Rubello D; Cecchin D; Canzonieri V
Clin Nucl Med; 2012 Aug; 37(8):e184-8. PubMed ID: 22785525
[TBL] [Abstract][Full Text] [Related]
16. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
[TBL] [Abstract][Full Text] [Related]
17. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [
Glickman A; Paredes P; Carreras-Diéguez N; Niñerola-Baizán A; Gaba L; Pahisa J; Fusté P; Del Pino M; Díaz-Feijóo B; González-Bosquet E; Agustí N; Sánchez-Izquierdo N; Fuster D; Perissinotti A; Romero I; Fernández-Galán E; Carrasco JL; Gil-Ibáñez B; Torné A
Eur Radiol; 2022 Apr; 32(4):2200-2208. PubMed ID: 34586465
[TBL] [Abstract][Full Text] [Related]
19.
García-Talavera P; Alejo E; Arias P; Verdú A; Tamayo P; Gómez-Caminero F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(4):207-213. PubMed ID: 34218882
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]